Clinical Characteristics, Microbiological Profile, and Antimicrobial Resistance of Pseudomonas aeruginosa in Hospitalized Patients with Bronchiectasis: A 10-Year Single- Center Cohort Study
This 10-year single-center cohort study in Beijing reveals that *Pseudomonas aeruginosa* is the predominant respiratory pathogen in hospitalized bronchiectasis patients, where its colonization is independently associated with more severe structural lung disease, systemic inflammation, and prolonged hospitalization, while also highlighting significant rates of carbapenem and fluoroquinolone resistance that necessitate enhanced surveillance and stewardship.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the lungs as a vast, branching network of airways, designed to move air in and out with effortless grace. In a healthy person, these tubes remain smooth and open. But for some, the walls of these airways become permanently damaged, stretching out and losing their ability to clear mucus. This condition is called bronchiectasis. When the airways are widened and scarred, they become a perfect trap for bacteria, which settle in the stagnant mucus and cause repeated infections. Among the many germs that can take hold, one is particularly notorious for its ability to cause severe, long-term illness: a bacterium called Pseudomonas aeruginosa. This organism is a master of survival, often developing defenses that make standard medicines ineffective. Understanding how this specific germ behaves in the lungs of patients in mainland China has been a missing piece of the puzzle, leaving doctors to guess at the best ways to treat these difficult cases.
To fill this gap, researchers at Beijing Chao-Yang Hospital, a major respiratory center, looked back over a decade of medical records. They examined the files of nearly 2,500 unique adults who had been admitted to the hospital for bronchiectasis between 2014 and 2024. The team did not just count how many people were sick; they dug deep into the details of each hospital stay, looking at symptoms, blood test results, and the specific bacteria found in the patients' sputum. They focused on a critical question: how does the presence of Pseudomonas aeruginosa change the course of the disease, and how resistant is this germ to the antibiotics doctors use to fight it?
The study revealed that Pseudomonas aeruginosa is the most common culprit in these severe cases. Out of nearly 1,000 hospital admissions where a respiratory culture was taken, the bacterium was found in more than one-third of them. This was far more frequent than any other germ, including Klebsiella pneumoniae or Aspergillus fungi. When the researchers compared the patients who carried this bacterium against those who did not, a clear picture of a more severe illness emerged. The patients with Pseudomonas were slightly younger on average, but their hospital stays were longer, lasting a median of 12 days compared to 11 days for others. Their bodies showed signs of a stronger battle, with higher white blood cell counts and higher platelet levels, indicating a more intense inflammatory response. Perhaps most telling was the state of their breathing; these patients had higher levels of carbon dioxide in their blood, a sign that their lungs were struggling to clear waste gas effectively.
The researchers also looked for the specific factors that made a patient more likely to carry this difficult bacterium. They found that the extent of the physical damage to the lungs, as seen on a CT scan, was a major predictor. Patients whose scans showed clear evidence of the widened airways were significantly more likely to be colonized by the germ. Surprisingly, older age appeared to be a protective factor, with older patients less likely to carry the infection than their younger counterparts. The study also noted that patients with this bacterium incurred higher costs for antibiotics during their stay, reflecting the need for stronger, more specialized medicines.
Perhaps the most urgent finding concerned the strength of the bacteria itself. The researchers tested how well different antibiotics could kill the Pseudomonas strains they collected. The results showed a worrying trend: nearly a quarter of the bacteria were resistant to carbapenems, a powerful class of antibiotics often used as a last resort. Another quarter were resistant to fluoroquinolones, another common group of drugs. This means that for a significant portion of these patients, the usual weapons in the medical arsenal were no longer effective. However, there was a glimmer of hope. The study found that two older classes of antibiotics, amikacin and tobramycin, remained highly effective against the vast majority of the bacteria, with susceptibility rates exceeding 90 percent. This suggests that while the bacteria are evolving, there are still specific tools that can work if chosen carefully.
The impact of this infection extended beyond the immediate hospital stay. The researchers found that the presence of structural lung damage, visible on CT scans, was the strongest predictor of a patient returning to the hospital for another round of treatment. This creates a cycle where the physical damage invites the bacteria, and the bacteria cause further damage and more frequent hospital visits. The study concludes that in Beijing, Pseudomonas aeruginosa is the dominant threat to patients with bronchiectasis, driving longer stays, higher costs, and more severe breathing problems. The high rates of resistance to common drugs highlight an urgent need for doctors to test patients regularly and choose antibiotics based on what the specific bacteria in that patient are capable of resisting, rather than guessing. By understanding the local landscape of this germ, medical teams can better protect these vulnerable patients and break the cycle of repeated illness.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.